Biogen Idec, Elan MS drug to return to market (bizjournals.com via Yahoo! Finance)
Biogen Idec Inc. and Elan Corp. PLC reportedly won approval from a key Food and Drug Administration committee to resume sales of Tysabri, a multiple sclerosis drug that was withdrawn a year ago after two patients died from a rare brain infection.